General Information of Drug (ID: DMF6W5K)

Drug Name
AL003 Drug Info
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMF6W5K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gemtuzumab ozogamicin DMJ2O7B Acute myeloid leukaemia 2A60 Approved [3]
Vadastuximab talirine DM9LH10 Acute myeloid leukaemia 2A60 Phase 3 [4]
Actimab-A DMKBIPR Acute myeloid leukaemia 2A60 Phase 2 [4]
BI-836858 DMUVMY9 Myelodysplastic syndrome 2A37 Phase 2 [5]
Actimab-MDS DMP8EEX Myelodysplastic syndrome 2A37 Phase 2 [6]
GTB-3550 DMK2RIB Acute myelogenous leukaemia 2A41 Phase 1/2 [7]
SGN-CD33A DMRC7PI Acute myeloid leukaemia 2A60 Phase 1/2 [8]
CART33 cells DM81JIT Myeloid leukaemia 2B33.1 Phase 1/2 [9]
CD33-specific gene-engineered T cells DMM35D2 Acute myeloid leukaemia 2A60 Phase 1/2 [10]
Anti-CD33 CAR-T cells DM9NPF6 Myeloid leukaemia 2B33.1 Phase 1/2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03822208) A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL003 in Healthy Participants and in Participants With Mild to Moderate Alzheimer's Disease.. U.S.National Institutes of Health.
2 A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Front Immunol. 2020 Mar 31;11:456.
3 Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53.
6 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals
7 Clinical pipeline report, company report or official report of GT Biopharma.
8 SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.
9 ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33
10 ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
11 ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies